Alert detail
LCD L38303: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease — CGS
Policy ID: LCD-L38303Specialty: OncologyAdded: 6/5/2026Effective: 2026-03-19lcd
What changed
New genomic classifier coverage supports compliance with updated rates for prostate cancer.
Who’s affected: Oncology billing teams · Effective: 2026-03-19
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.
Not ready to subscribe?
Get the free weekly reimbursement brief for Oncology— the week’s changes and deadlines, delivered to your inbox. No account required.